{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T04:21:52Z","timestamp":1764044512307},"reference-count":72,"publisher":"Informa UK Limited","issue":"22","funder":[{"name":"Spanish Society of Medical Oncology"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2016,11,30]]},"DOI":"10.2217\/fon-2016-0132","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T13:32:40Z","timestamp":1469712760000},"page":"2545-2560","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["Selumetinib in the Treatment of Non-Small-Cell Lung Cancer"],"prefix":"10.1080","volume":"12","author":[{"given":"Reyes","family":"Bernab\u00e9","sequence":"first","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Hospital Valme, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Patrao","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Carter","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Blackhall","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, UK"},{"name":"The University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Dean","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, UK"},{"name":"The University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"Globocan\n. Lung cancer estimated incidence mortality and prevalence worldwide in 2012 (2012). http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60735-0"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.07.093"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.09.005"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2365"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70270-X"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.11.010"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4389"},{"key":"e_1_3_2_13_1","unstructured":"ClinicalTrials.gov\n. https:\/\/clinicaltrials.gov"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.8"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.17.7686"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.29.18623"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.185"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0323-5"},{"issue":"1","key":"e_1_3_2_19_1","first-page":"12","article-title":"Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis","volume":"83","author":"Fantl JA","year":"1994","unstructured":"Fantl JA , CardozoL, McClishDKet al. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. Obstet. Gynecol.83(1), 12\u201318 (1994).","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.8027","article-title":"Oral MEK1\/2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): a Phase I\/Ib trial","volume":"31","author":"Kelly K","year":"2013","unstructured":"Kelly K , MazieresJ, LeighlNet al. Oral MEK1\/2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): a Phase I\/Ib trial. J. Clin. Oncol.31(Suppl.), Abstract 8027 (2013).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1920"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0341"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.2506","article-title":"Dose escalation stage of a first-in-class Phase I study of the novel oral ERK 1\/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors","volume":"33","author":"Infante JR","year":"2015","unstructured":"Infante JR , JankuF, TolcherAWet al. Dose escalation stage of a first-in-class Phase I study of the novel oral ERK 1\/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. J. Clin. Oncol.33(Suppl.), Abstract 2506 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1311"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9473"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.03.016"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0212-z"},{"issue":"1","key":"e_1_3_2_28_1","first-page":"4","article-title":"Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer","volume":"75","author":"Hotcher HS","year":"2015","unstructured":"Hotcher HS , UbojaN, MessersmithWet al. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother. Pharmacol.75(1), 4\u201323 (2015).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9392-8"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.04.005"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9432"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu054"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70237-7"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1491"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1076"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Widemann BC MarcusJL FisherMJet al. Phase I Study of the MEK1\/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). J. Clin. Oncol. 32(5 Suppl.) Abstract 10.18 (2014).","DOI":"10.1200\/jco.2014.32.15_suppl.10018"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70572-7"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0979"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9687-4"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.126"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0563"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209288"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6096"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1150"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0231"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4956"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1440"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1890"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014124"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2324"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1780"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10937"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2483"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1732-7"},{"key":"e_1_3_2_55_1","volume-title":"ACCR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics.","author":"Kim K","year":"2011","unstructured":"Kim K , InfanteJ, CohenRet al. A Phase I dose-escalation study of selumetinib in combination with Docetaxel in patients with advanced solid tumors. Presented at: ACCR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics.San Francisco, CA, USA, 12\u201316 November 2011 (Abstract B225)."},{"key":"e_1_3_2_56_1","volume-title":"ESMO 2014 Congress.","author":"Emma Dean E","year":"2014","unstructured":"Emma Dean E , SteeleN, ArkenauHet al. A Phase I study of the MEK1\/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC. Presented at: ESMO 2014 Congress.Madrid, Spain, 26\u201330 September 2014 (Abstract P1242)."},{"key":"e_1_3_2_57_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8046","article-title":"A Phase Ib study of selumetinib in patients (pts) with previously untreated metastatic non-small cell lung cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group NCT01783197. ASCO Annual Meeting","volume":"33","author":"Nicholas GA","year":"2015","unstructured":"Nicholas GA , GoffinJ, LaurieSet al. A Phase Ib study of selumetinib in patients (pts) with previously untreated metastatic non-small cell lung cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group NCT01783197. ASCO Annual Meeting. J. Clin. Oncol.33(Suppl.), Abstract 8046 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_58_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.2583","article-title":"A Phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors. ASCO Annual Meeting","volume":"33","author":"Saka W","year":"2015","unstructured":"Saka W , Simon PaceyS, BlackhallFet al. A Phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors. ASCO Annual Meeting. J. Clin. Oncol.33(Suppl.), Abstract 2583 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_59_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.2509","article-title":"Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer","volume":"33","author":"Oxnard GR","year":"2015","unstructured":"Oxnard GR , RamalingamSS, AhnM-J. Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. J. Clin. Oncol.33(Suppl.), Abstract 2509 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_60_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS2607","article-title":"SELECT-4: Phase I dose escalation trial of Selumetinib (AZD6244, ARRY-142886) in combination with durvalumab (MEDI4736) in patients with advanced solid tumours","volume":"34","author":"Janne PA","year":"2016","unstructured":"Janne PA , GhiorhiuDC, SmithPDet al. SELECT-4: Phase I dose escalation trial of Selumetinib (AZD6244, ARRY-142886) in combination with durvalumab (MEDI4736) in patients with advanced solid tumours. J. Clin. Oncol.34(Suppl.), Abstract TPS2607 (2016).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014124"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0163-9"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1901"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2958"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181e8b3a3"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70489-8"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.215"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw008"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.12.010"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.2007"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.8433"},{"issue":"3","key":"e_1_3_2_72_1","first-page":"33","article-title":"An overview of the design and conduct of the BATTLE trials","volume":"4","author":"Liu S","year":"2015","unstructured":"Liu S , LeeJ. An overview of the design and conduct of the BATTLE trials. Chin. Clin. Oncol.4(3), 33\u201346 (2015).","journal-title":"Chin. Clin. Oncol."},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9567-3"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70489-8"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2016-0132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:38Z","timestamp":1719125018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2016-0132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":72,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2016,11,30]]}},"alternative-id":["10.2217\/fon-2016-0132"],"URL":"https:\/\/doi.org\/10.2217\/fon-2016-0132","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}